TEVA-LENOLTEC NO. 4 60 MG — DIN 00621463
CODEINE PHOSPHATE : 60 MG ACETAMINOPHEN : 300 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-LENOLTEC NO. 4?
TEVA-LENOLTEC NO. 4 60 MG contains CODEINE PHOSPHATE : 60 MG ACETAMINOPHEN : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 00621463, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-LENOLTEC NO. 4 used for?
Short-term relief of moderate to severe pain in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Codeine And Paracetamol cost around the world?
Codeine And Paracetamol is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Hungary publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 31 | 42 | ZAR███.██ |
| Morocco | PPV (public price) | 6 | 6 | MAD███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| United States | acquisition | 3 | 5 | USD███.██ |
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
65 pack listings across 49 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Codeine And Paracetamol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Codeine And Paracetamol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
22 holders have a Canadian DIN containing Codeine And Paracetamol, across 66 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 6 | 6 | ACETAMINOPHEN WITH CODEINE - CAPLET, TEVA-EMTEC-30, TEVA-LENOLTEC NO. 1, TEVA-LENOLTEC NO. 2, TEVA-LENOLTEC NO. 3, +1 more | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 6 | 2 | ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE TABLETS, ACETAMINOPHENE CODEINE ET CAFEINE CAPLETS, ACETAMINOPHENE CODEINE ET CAFEINE FORT, TRIATEC-30, TRIATEC-8, +1 more | Sourceable in Canada |
| PHARMASCIENCE INC | 14 | 1 | ACET 2, ACET 3, ACET CODEINE 30, ACET CODEINE 60, ACETAMINOPHEN 500 MG COMPOUND TABLETS WITH CODEINE, +8 more | Sourceable in Canada |
| CELLCHEM PHARMACEUTICALS INC. | 4 | 0 | ACETAMINOPHEN 500MG, CAFFEINE AND 8MG CODEINE PHOSPHATE, ACETAMINOPHEN, CAFFEINE AND 8 MG OF CODEINE PHOSPHATE TABLETS, ACETAMINOPHEN, CAFFEINE, AND 8MG OF CODEINE PHOSPHATE TABLETS, MUSCLE AND BACK PAIN RELIEF - 8 TABLETS | No marketed DIN |
| JANSSEN INC | 4 | 0 | TYLENOL WITH CODEINE ELIXIR, TYLENOL WITH CODEINE NO. 2 - TAB, TYLENOL WITH CODEINE NO. 3 - TAB, TYLENOL WITH CODEINE NO. 4 | No marketed DIN |
| NOVOPHARM LIMITED | 4 | 0 | ACETAMINOPHEN CAFFEINE & 8MG COD. PHOS. TAB, NOVO-GESIC C15, NOVO-GESIC C30, NOVO-GESIC-C8 | No marketed DIN |
| CHURCH & DWIGHT CANADA CORP | 3 | 0 | ATASOL 15, ATASOL 30, ATASOL 8 | No marketed DIN |
| MCNEIL PHARMACEUTICAL, DIVISION OF ORTHO-MCNEIL INC. | 3 | 0 | TYLENOL NO 1 TAB, TYLENOL NO1 FORTE TABLETS WITH CODEINE, TYLENOL WITH CODEINE ELIXIR | No marketed DIN |
| MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | 3 | 0 | EXDOL 15TAB, EXDOL 30TAB, EXDOL 8 TAB | No marketed DIN |
| GLAXOSMITHKLINE INC | 2 | 0 | EMPRACET-30, EMPRACET-60 | No marketed DIN |
| JAMP PHARMA CORPORATION | 2 | 0 | ACETAMINOPHEN ELIXIR WITH 8MG CODEINE PHOSPHATE SYRUP, ACETAMINOPHEN, CAFFEINE & 8MG CODEINE PHOSPHATE TABLETS | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 2 | 0 | (EXTRA STRENGTH) ACETAMINOPHEN, CAFFEINE & 8MG CODEINE PHOSPHATE CAPLETS, ACETAMINOPHEN CAFFEINE & 8MG COD PHOS TAB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 60 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section). |
| Storage | Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section). General instruction to store securely to avoid theft or misuse. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Codeine And Paracetamol |
|---|---|
| ATC code | N02AJ06 |
| AHFS class | 28:08.08 ; 28:08.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00621463 |
|---|---|
| DIN (unpadded, as printed on some documents) | 621463 |
| Brand name | TEVA-LENOLTEC NO. 4 |
| Generic / active ingredient | CODEINE PHOSPHATE : 60 MG ACETAMINOPHEN : 300 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | NARCOTICS (CDSA I) |
| ATC code | N02AJ06 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02AJ |
| Current status | MARKETED |
| Status date | 05-Oct-2018 |
| Original market date | 1986-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Short-term relief of moderate to severe pain. Tablets must be swallowed whole. Use lowest effective dose for shortest period. Dosage should be individualized and titrated based on response.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; GI obstruction; asthma/COPD; respiratory depression; acute alcoholism; head injury; MAOIs; nursing/labour; children <12; pediatric tonsillectomy/adenoidectomy; CYP2D6 ultra-metabolizers.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and fatal respiratory depression. Use with benzodiazepines or alcohol may result in death. Risk of death in CYP2D6 ultra-rapid metabolizers.
Is Codeine And Paracetamol in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PURDUE PHARMA, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 66 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETAMINOPHEN WITH CODEINE - CAPLET | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02143933 |
| ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE TABLETS | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02154234 |
| PMS-ACETAMINOPHEN WITH CODEINE ELIXIR | 8 MG / 5 ML | ELIXIR | PHARMASCIENCE INC | MARKETED | 00816027 |
| TEVA-EMTEC-30 | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00608882 |
| TEVA-LENOLTEC NO. 1 | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00653233 |
| TEVA-LENOLTEC NO. 2 | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00653241 |
| TEVA-LENOLTEC NO. 3 | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00653276 |
| TRIATEC-30 | 300 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00789828 |
| (EXTRA STRENGTH) ACETAMINOPHEN, CAFFEINE & 8MG CODEINE PHOSPHATE CAPLETS | 15 MG | TABLET | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | 02236871 |
| ACET 2 | 15 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 00706515 |
2 · Same class — other molecules in ATC N02AJ
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Codeine And Paracetamol | (EXTRA STRENGTH) ACETAMINOPHEN, CAFFEINE & 8MG CODEINE PHOSPHATE CAPLETS · ACET 2 · ACET 3 · ACET CODEINE 30 · +60 more | 66 | 9 | Yes |
| Tramadol And Paracetamol | ACT TRAMADOL/ACET · AG-ACET-TRAMADOL · APO-TRAMADOL/ACET · AURO-TRAMADOL/ACETAMINOPHEN · +20 more | 24 | 8 | Yes |
| Oxycodone And Paracetamol | APO-OXYCODONE/ACET · ENDOCET · NTP-OXYCODONE ACETAMINOPHEN · NU-OXYCODONE/ACET · +10 more | 14 | 3 | Yes |
| Oxycodone And Acetylsalicylic Acid | ENDODAN · PERCODAN · PERCODAN-DEMI · RIVACODAN · +1 more | 5 | 1 | Yes |
| Codeine And Acetylsalicylic Acid | 222 TABLETS · 282 TAB · 282 TABLETS · 292 TAB · +21 more | 26 | 0 | Not in Canada |
| Hydrocodone And Ibuprofen | CODOFEN · IBUCODONE | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02AA | Codein, Combinations With Psycholeptics · Codeine, Combinations Excl. Psycholeptics · Hydromorphone · Morphine · Natural Opium Alkaloids · +3 more | 378 | 129 |
| N02AX | Tapentadol · Tramadol | 41 | 30 |
| N02AB | Fentanyl · Pethidine | 105 | 17 |
| N02AE | Buprenorphine | 15 | 4 |
| N02AF | Butorphanol · Nalbufine | 5 | 2 |
| N02AC | Dextropropoxyphene · Dextropropoxyphene, Comb Excl Psycholept | 7 | 0 |
| N02AD | Pentazocine | 3 | 0 |
| N02AG | Opioids In Comb With Antispasmodics | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-LENOLTEC NO. 4 called?
The same molecule, Codeine And Paracetamol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Brunacod | Latin | South Africa |
| Ibupain Forte | Latin | South Africa |
| Spectrapain | Latin | South Africa |
| Codef Cough | Latin | South Africa |
| Docsed | Latin | South Africa |
| Lenazine Forte | Latin | South Africa |
| Mybucod | Latin | South Africa |
| Suncodin Tablets | Latin | South Africa |
| ACTIFED COMPOUND LINCTUS | Latin | Saudi Arabia |
| Adco-Kiddipayne | Latin | South Africa |
| Adco-Metaxol | Latin | South Africa |
| AstraPain Syrup | Latin | South Africa |
| Ban Pain A/F | Latin | South Africa |
| Codeine | Latin | South Africa |
| CODETUX AD | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.